Skip to content
Menu

Bernstein Downgrades Summit Therapeutics to Underperform, Lowers Price Target to $8.3

Benzinga Newsdesk 18 hours ago

Analyst RatingsNewsDowngradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.

Bernstein analyst Jeffrey Walch downgrades Summit Therapeutics (NASDAQ:SMMT) from Market Perform to Underperform and lowers the price target from $11.9 to $8.3.

Read at benzinga.com